Several biopharma companies reshuffled legal leadership, signaling ongoing emphasis on compliance, governance, and deal readiness. Aquestive Therapeutics appointed Thomas A. Zalewski as chief legal and compliance officer, replacing Lori J. Braender in the COO/CLO role while Braender remains corporate secretary. Arcutis Biotherapeutics promoted Mas Matsuda from senior vice president and general counsel to executive vice president, chief legal officer, and corporate secretary. Arcutis highlighted Matsuda’s role during a period that included six FDA approvals for its ZORYVE therapy. Separately, Greenberg Traurig added Beverly Oliver to its Health Care and FDA practice as a shareholder in Dallas. While these changes are not pipeline events, they can matter for investors and partners because legal leadership often drives how companies manage regulatory risk in commercial operations, licensing, and future M&A.